Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GGT1 | P19440 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10964895 | 0.87 | CTNNB1 (0.54) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL28411450 | 0.86 | CTNNB1 (0.66) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL11574490 | 0.84 | HTT (0.55) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL11576380 | 0.84 | CTNNB1 (0.51) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL9252102 | 0.83 | CTNNB1 (0.67) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL1798 | 0.82 | CTNNB1 (0.71) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL30775034 | 0.81 | HTT (0.59) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL366 | 0.81 | HTT (0.59) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL2863787 | 0.81 | HTT (0.69) | HTTCTNNB1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL6049205 | 0.81 | TSHR (0.54) | HTR2ASLC6A4KCNH2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1184372-B1 | Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) | PFIZER LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-6630504-B2 | Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction | PFIZER INC. | 2003-10-07 | — | — | US | disclosed |
| US-20020183303-A1 | Phenoxyphenylheterocyclyl derivatives as SSRIs | PFIZER INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1184372-A1 | Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) | Pfizer Limited (GB) | 2002-03-06 | — | — | EP | disclosed |
| US-4094900-A | Method of preparing aryloxybenzoic and arylthiobenzoic acids | SMITHKLINE CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183303-A1 | Phenoxyphenylheterocyclyl derivatives as SSRIs | CRHR1, NR3C1, HTR6 | HTT 2753/4885CTNNB1 1566/4885HTR2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.